Published in Medical Letter on the CDC and FDA, August 30th, 2009
"In the first half of the year, CombinatoRx has entered into a merger agreement with Neuromed, a late-stage product company, entered into a significant research alliance with Novartis, reported positive clinical data on three drug candidates, published key scientific findings in Nature Biotechnology, improved the financial terms in our Fovea product development collaboration and renegotiated the lease on our office and lab space to significantly reduce our long-term financial obligations," commented Robert Forrester, Interim President and CEO of CombinatoRx....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA